Soluble Guanylate Cyclase Stimulator Drug Class List

Drugs in Drug Class: Soluble Guanylate Cyclase Stimulator

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-002	Jan 19, 2021		RX	Yes	No	8,420,656		Y	Y
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-001	Jan 19, 2021		RX	Yes	No	8,420,656		Y	Y
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes	8,420,656		Y	Y
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-002	Jan 19, 2021		RX	Yes	No
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-001	Jan 19, 2021		RX	Yes	No
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-002	Jan 19, 2021		RX	Yes	No

Market dynamics and patent landscape for soluble guanylate cyclase stimulators

Last updated: April 25, 2026

What defines the soluble guanylate cyclase (sGC) stimulator market?

Soluble guanylate cyclase stimulators are cardiovascular- and pulmonary-hypertension–focused small molecules that activate sGC signaling to increase cyclic GMP. Commercial uptake depends on (1) line-of-therapy fit in pulmonary arterial hypertension (PAH) and related conditions, (2) dosing simplicity and tolerability, (3) payer coverage and contracting, and (4) competitive positioning versus PDE5 inhibitors and other pathway agents (prostacyclin pathway, endothelin pathway).

The market divides by mechanism variant:

• sGC stimulators (direct stimulators of sGC)
• sGC activators (typically act under oxidative conditions; distinct IP and molecule families)

This analysis covers sGC stimulators (not activators), which include the marketed product riociguat and next-generation programs seeking improved pharmacology, safety, or differentiation (dose, formulation, patient selection).

Which products anchor the current sGC stimulator franchise?

Market anchor: riociguat

• Riociguat (Adempas) is the only widely established, directly marketed sGC stimulator across PAH and chronic thromboembolic pulmonary hypertension (CTEPH) after endarterectomy or when inoperable.
• It has regulatory approval and a mature evidence base; its patent estate and lifecycle-management strategy drive the near-to-midterm competitive entry timeline.

Business implication: new sGC stimulators must either (a) displace riociguat clinically, or (b) capture specific segments through superior onset, safety, drug-drug interaction profile, or adherence.

How does the competitive landscape shape dosing and IP strategy?

Competitive substitution and category pressure

Payers and clinicians already have PAH/CTEPH pathway options:

• PDE5 inhibitors
• Endothelin receptor antagonists
• Prostacyclin agents (including receptor agonists and delivery systems)
• Combination therapies

What this means for sGC stimulators: entry is most feasible where:

• the clinical guideline pathway supports sGC as add-on or combination partner,
• the patient profile aligns with safety/tolerability advantages,
• or the product offers a clear operational benefit (e.g., fewer dose adjustments, simplified titration, better consistency).

Differentiation vectors that show up in patents

Across sGC stimulator portfolios, patent filings concentrate around:

• novel heteroaromatic cores and substituent patterns (composition-of-matter)
• regioisomer/polymorph/crystal form strategies (formulation and solid-state IP)
• salt selection and prodrug approaches (solubility, stability, and exposure control)
• method-of-use claims (patient subtypes, combination regimens, dosing schedules)

What is the patent landscape structure for soluble guanylate cyclase stimulators?

A typical sGC stimulator patent estate spans:

1. Core composition-of-matter for the initial molecule
2. Solid form IP (crystal forms, polymorphs, solvates, hydrates)
3. Salt and intermediate IP
4. Manufacturing process IP (routes, purification, crystallization conditions)
5. Formulation IP (tablet compositions, coatings, particle size distributions)
6. Clinical use IP (expanded indications, subpopulations, combinations, titration approaches)

How to read “distance” to expiry

For investment and R&D timing, the critical question is not the nominal compound patent term alone. The practical exclusivity gap typically depends on:

• last listed composition-of-matter expiration
• whether key solid-state or salt patents remain in force after compound expiry
• whether method-of-use patents are enforceable in major jurisdictions
• regulatory exclusivities that delay generic substitution

What is the riociguat patent and exclusivity framework?

Core molecule and lifecycle management

Riociguat is protected by a layered IP estate that includes:

• composition-of-matter patents for the drug molecule
• solid form and formulation patents (crystalline forms, salts, tablets)
• manufacturing process patents

These layers can outlast the earliest composition patent and create a “patent thicket” effect in jurisdictions with active enforcement and multiple filings.

Business implication: generic entry risk depends on whether ANDA-type challengers can design around composition claims while also avoiding active solid form and formulation claims. Even where the base molecule composition expires, remaining solid-state and formulation protections can delay generic market entry.

Where are the patent filing hotspots for sGC stimulators?

Jurisdiction pattern (practical view for investors)

For US and EU commercialization, the filing hotspots usually follow regulatory and enforcement strength:

• US for broad composition and method claims
• EP for European market leverage and litigation posture
• WO/PCT as the umbrella for global filing families
• other major markets where enforcement economics justify local filing

The strongest estates typically show:

• dense family coverage around the active substance,
• multiple fallback positions (solid form, salt, formulation, and method-of-use),
• and clear priority chains.

What product pipelines are most likely to challenge riociguat?

A challenger sGC stimulator generally aims for one or more of the following:

• improved potency or exposure control to reduce titration burden
• better tolerability (hypotension-related adverse event mitigation)
• improved pharmacokinetics in comorbid populations
• novel fixed-dose approaches that simplify chronic therapy
• earlier-stage clinical differentiation through endpoints in PAH subtypes

From a patent-landscape perspective, the most “investable” pipelines are the ones with:

• at least one strong composition-of-matter family that is not fully dependent on the riociguat scaffold
• a robust solid-state strategy to secure exclusivity beyond compound term
• method-of-use and combination claims that map to current clinical practice

What does market access mean for sGC stimulator uptake?

Pricing and contracting logic

Payers typically scrutinize:

• cost-effectiveness versus other PAH regimens
• incremental benefit within guideline-supported sequences
• total regimen cost, including combination therapy expense

Because sGC stimulators are often used in combination settings, contracting usually reflects combination value, not only drug acquisition cost.

Evidence and guideline placement

Guideline placement drives:

• physician prescribing behavior
• payer criteria for authorization
• formulary tier decisions

For entrants, the most valuable claims are those aligned to:

• PAH disease stage (incident vs prevalent)
• CTEPH eligibility subsets
• combination therapy regimes

How does generic and biosimilar-style competition risk appear for this class?

sGC stimulators are small molecules; therefore, generic competition is expected after patent and exclusivity expiration. The risk profile is shaped by:

• whether the reference listed product has multiple late-expiring solid form or formulation patents
• whether generic applicants must pursue a design-around that affects bioequivalence
• whether method-of-use patents remain enforceable in the relevant jurisdiction

Business implication: for riociguat, “real exclusivity” is likely the later expiry among solid-state/formulation and method-of-use families, not only the earliest compound patent.

What patent claims are typically enforceable against follow-ons?

In practice, follow-on generic or “authorized” competition must navigate:

• composition-of-matter claims covering the exact molecule (hard to design around)
• salt/polymorph claims that cover critical solid-state properties
• formulation claims tied to the marketed dosage form
• method-of-use claims that cover clinical regimens

The enforceability map for decision-making

For each major jurisdiction, the highest-impact questions for a competitive entry plan are:

• Do any solid form patents remain in force at the planned launch date?
• Are tablets or dosing formulations protected by specific composition of excipients and processing?
• Are combination regimens (with PDE5 inhibitors or endothelin pathway drugs) claimed in enforceable method claims?

Key actionable takeaways for investors and BD teams

• The sGC stimulator market is anchored by riociguat, and competitive entry hinges on layered IP that typically includes solid-state and formulation claims beyond base composition expiry.
• Successful challengers in sGC stimulators must differentiate on clinical value and operational dosing while protecting IP with multiple fallback positions (composition, solid form, and method-of-use).
• Generic risk timelines for riociguat depend on the latest enforceable patent families, not the first priority. A late-expiring solid form or formulation patent can materially shift entry timing.

---

Key Takeaways

• sGC stimulator demand is concentrated in PAH/CTEPH settings and is shaped by guideline-driven combination therapy and payer contracting.
• Riociguat anchors the class; the patent estate structure typically spans compound, solid-state, formulation, manufacturing, and method-of-use layers.
• Patent “distance” to expiry must be measured across the full stack of enforceable claims, since solid-state and formulation protections can outlast base compound patents.
• For pipeline entrants, the highest-probability IP path is a portfolio that covers composition plus solid form and dosing/formulation, with method-of-use claims aligned to current clinical sequences.

---

FAQs

1) What is the main commercial product in soluble guanylate cyclase stimulation?
Riociguat (Adempas) is the primary marketed sGC stimulator product with PAH and CTEPH positioning.

2) Why do solid-state and formulation patents matter in this class?
Because they can extend practical exclusivity even after the base composition-of-matter approaches expiry, limiting generic design-around options.

3) What claim types most constrain follow-on competition?
Composition-of-matter claims, followed by solid-state (polymorph/salt) and formulation claims, with method-of-use claims adding additional enforcement leverage.

4) How do clinical guidelines influence market uptake?
Guideline placement drives prescribing and payer authorization, which favors products aligned to the sequence of therapy used in real practice.

5) What differentiation is most relevant for sGC stimulator entrants?
Clinical benefit within PAH/CTEPH subgroups plus operational advantages such as simplified dosing/titration and improved tolerability, supported by layered IP coverage.

---

References

[1] U.S. Food and Drug Administration. Adempas (riociguat) prescribing information. FDA label.
[2] U.S. Patent and Trademark Office. Patent prosecution and publication records for riociguat and soluble guanylate cyclase stimulator patent families (public PAIR and published applications).
[3] European Medicines Agency. Adempas (riociguat) product information and assessment documents. EMA.